Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating activities:
Net loss	$ (28,638,778)	$ (6,223,165)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	6,603	7,853
Stock-based compensation expense	366,383	393,471
Common stock issued for advisory services	0	487,500
Warrant related expense and change in fair value	26,015,746	0
Non-cash interest expense	57,185	3,383
Changes in operating assets and liabilities:
Prepaid expenses, deposits and other assets	(99,737)	(97,058)
Accounts payable, accrued expenses and other liabilities	(1,123,303)	797,827
Net cash used in operating activities	(3,415,901)	(4,630,189)
Cash flows (used in) provided by investing activities:
Purchases of property and equipment	(6,372)	(1,994)
Cash received in reverse merger transaction	0	8,500,602
Net cash (used in) provided by investing activities	(6,372)	8,498,608
Cash flows provided by financing activities:
Proceeds from the sale of Series A convertible preferred stock, net	14,269,095	0
Payment of offering costs	(187,649)	0
Net cash provided by financing activities	14,081,446	0
Net increase in cash and cash equivalents	10,659,173	3,868,419
Cash and cash equivalents at beginning of period	1,552,852	1,997,192
Cash and cash equivalents at end of period	12,212,025	5,865,611
Supplemental disclosure of non-cash investing and financing activities:
Reclassification of deferred offering costs upon completion of private placement	180,456	0
Offering costs in accounts payable and accrued expenses	178,258	0
Series A cumulative preferred dividends	(58,845)	0
Issuance of subscription receivable upon sale of Series A convertible preferred stock	(8,280,935)	0
Conversion of convertible notes and related accrued interest into common stock	0	711,495
Consideration in connection with RestorGenex Corporation merger transaction	$ 0	$ 21,261,000